Stock analysts at BTIG Research began coverage on shares of Illumina (NASDAQ:ILMN) in a research report issued on Friday, MarketBeat Ratings reports. The brokerage set a “neutral” rating on the life sciences company’s stock.
Several other brokerages have also recently issued reports on ILMN. Evercore ISI assumed coverage on Illumina in a research note on Wednesday. They set an “outperform” rating and a $250.00 price objective on the stock. Piper Jaffray Companies raised their price objective on Illumina to $274.00 and gave the stock an “overweight” rating in a research note on Thursday. Wells Fargo & Co upgraded Illumina from a “market perform” rating to an “outperform” rating and set a $205.00 price objective on the stock in a research note on Tuesday, January 2nd. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, December 26th. Finally, Morgan Stanley raised their price objective on Illumina from $122.00 to $135.00 and gave the stock an “underweight” rating in a research note on Thursday, December 14th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $211.88.
Illumina (NASDAQ ILMN) opened at $228.17 on Friday. Illumina has a one year low of $137.40 and a one year high of $233.54. The stock has a market capitalization of $33,312.82, a price-to-earnings ratio of 66.72, a P/E/G ratio of 3.13 and a beta of 0.79. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22.
In other news, Director Robert S. Epstein sold 1,250 shares of the firm’s stock in a transaction on Saturday, December 29th. The stock was sold at an average price of $217.38, for a total transaction of $271,725.00. Following the transaction, the director now directly owns 8,838 shares of the company’s stock, valued at $1,921,204.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Charles Dadswell sold 145 shares of the firm’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $224.50, for a total value of $32,552.50. Following the transaction, the senior vice president now directly owns 7,411 shares in the company, valued at $1,663,769.50. The disclosure for this sale can be found here. Insiders sold 158,921 shares of company stock worth $33,810,181 over the last quarter. 0.89% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the company. Intellectus Partners LLC increased its holdings in shares of Illumina by 6.6% during the second quarter. Intellectus Partners LLC now owns 10,783 shares of the life sciences company’s stock valued at $1,871,000 after purchasing an additional 664 shares during the period. Stephens Investment Management Group LLC increased its holdings in shares of Illumina by 0.5% during the second quarter. Stephens Investment Management Group LLC now owns 168,706 shares of the life sciences company’s stock valued at $29,274,000 after purchasing an additional 803 shares during the period. Axiom International Investors LLC DE increased its holdings in shares of Illumina by 60.9% during the third quarter. Axiom International Investors LLC DE now owns 186,457 shares of the life sciences company’s stock valued at $37,142,000 after purchasing an additional 70,572 shares during the period. Virtu Financial LLC acquired a new position in shares of Illumina during the third quarter valued at $577,000. Finally, Janus Henderson Group PLC increased its holdings in shares of Illumina by 1,556.2% during the second quarter. Janus Henderson Group PLC now owns 330,010 shares of the life sciences company’s stock valued at $57,263,000 after purchasing an additional 310,084 shares during the period. 91.60% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Illumina (ILMN) Now Covered by Analysts at BTIG Research” was originally reported by American Banking and Market News and is the sole property of of American Banking and Market News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/07/illumina-ilmn-now-covered-by-analysts-at-btig-research.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
